Clascoterone 1% cream in acne vulgaris: a profile of its use

AbstractClascoterone 1% cream (WINLEVI®) is an androgen receptor inhibitor approved for the topical treatment of acne vulgaris in patients aged ≥ 12 years in the USA. It is believed to compete with androgens (specifically Dihydrotestosterone) in binding to androgen receptors, thereby inhibiting downstream signaling of acnegenic pathways. In clinical trials, application of clascoterone 1% cream twice daily for 12 weeks was effective an d generally well tolerated in acne vulgaris patients, with a tolerability profile similar to that of the vehicle.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research